Ask AI
ProCE Banner Activity

ExpressPoints
Guideline Updates and Real-World Experiences in CLL: State-of-the-Art Evidence and Next Questions

Slideset

Download this short slideset of key takeaways from a live NCCN/CCO Webinar focused on current treatment in CLL/SLL.

Released: June 15, 2021

Expiration: June 14, 2022

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

BeiGene, Ltd.

Lilly

Pharmacyclics LLC and Janssen

Faculty Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Foresight Diagnostics, Genentech, Gilead, Interius, Miltenyi, Novartis, Roche, Seagen; researcher: Bristol Myers Squibb, Celgene, Cellectis, Genentech, Merck, Mustang Bio, Regeneron, Seagen, Takeda.

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE, has disclosed that he has received funds for research support from AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Johnson & Johnson, Loxo Oncology, Nurix, Genmab, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics and has received consulting fees from AbbVie, Acerta/AstraZeneca, Adaptive, Celgene, DTRM BioPharma, Johnson & Johnson, Nurix, Genmab, LOXO, Genentech, AZ, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem.

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas